Increasing Efficiency in Protein and Cell Production by Combining Single-Use Bioreactor Technology and Perfusion - An off-the-shelf, single-use perfusion system. - BioPharm International

ADVERTISEMENT

Increasing Efficiency in Protein and Cell Production by Combining Single-Use Bioreactor Technology and Perfusion
An off-the-shelf, single-use perfusion system.


BioPharm International Supplements
Volume 24, Issue 5, pp. s4-s11

INCREASE IN PRODUCTIVITY AND CELL DENSITY


Figure 5: Total Immunoglobulin (IgG) amount in batch and perfusion cultivations.
We have compared the productivity of recombinant anti–EpCAM in the bioreactor system operating in batch and perfusion mode. During the perfusion run, approximately 50 L of medium had been consumed, which was 10 times the amount that was used in batch mode. The maximum viable cell concentration was increased by a factor of 10. The total IgG yield in the perfusion run was 5900 mg, which was approximately 30 times greater than in the batch mode, where the total amount was 205 mg (see Figure 5). This illustrates that the perfusion system is perfectly suited for the fast production of high amounts of proteins such as monoclonal antibodies.

CONCLUSIONS

The authors demonstrated that an easy to use, off-the-shelf, single-use, bench-top perfusion bioreactor is capable of producing and supporting very high cell density cultures of up to 150 × 106 cells/mL. This approach can be applied to mediocre cell lines in order to quickly produce the amounts of recombinant proteins typically required during drug discovery or early development (e.g., for high throughput screening, or early preclinical studies in animals), and formulation development. Furthermore, this is a simple approach to improve the efficiency of seed production in large scale production. A typical seed train for a 1000 L bioreactor consists of a 50 L and 200 L bioreactor applying a dilution factor of 1:5 to 1:10 at maximum. Assuming an inoculum cell density of 5 × 105 cells/mL at 1000 L scale, which is equivalent to 5 × 1011 cells, this density can be achieved by approximately 20 L of a high cell density culture grown in a rocking-motion perfusion bioreactor. Certain limitations of this technology could be expected in larger bag systems, such as 100 L or 200 L rocking motion bags with integrated membranes for cell retention. The oxygen transfer rate in these systems is usually lower, and the ratio of membrane surface area to culture volume can not be scaled in a linear fashion due to size restrictions. While cell densities of 30-40 × 106 cells/mL have been reported for these larger scale rocking motion systems, it is likely that extreme high cell densities as reported in this article may not be reached.

THORSTEN ADAMS* is product manager, single use bioreactors, UTE NOACK is head of process engineering, upstream technology, TANJA FRICK is in upstream technology, GERHARD GRELLER is director, upstream technology, and CHRISTEL FENGE is vice-president, marketing and product management, fermentation, all at Sartoius Stedim Biotech, Göttingen, Germany,
.

REFERENCES

1. J.M. Coco-Martin, and M.M. Harmsen, BioProcess Int. 6 (S6), 28–33 (2008).

2. A. Salmen et. al., BioProcess Int. 7 (11), 34–39 (2009).

3. C. Fenge and E. Lüllau, "Cell Culture Bioreactors" in Cell Culture Technology For Pharmaceutical and Cell-Based Therapies, S. Ozturk, and W-S Hu, Eds. (Taylor & Francis, New York 2006), pp. 155–224.

4. J. Lim, et. al., BioPharm Int. 24 (2), 54–60 (2011).

5. R. Heidemann et. al., Cytotechnol. 38 (1–3), 99–108 (2002).

6. A. Amanullah et. al., Cell Culture Engineering IX conference, (Cancún, Mexico, March 2004).

7. R. Ohashi et. al., Biotechnol. Prog. 18 (6), 1292–1300 (2002).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here